[
    {
        "pregunta": "1. What are the recommendations for patients with RMD regarding the use of combined estrogen-progestin contraceptives?",
        "respuesta": "I don't know the specific recommendations for patients with rheumatic and musculoskeletal diseases (RMD) regarding the use of combined estrogen-progestin contraceptives. It is essential for patients to consult with their healthcare provider to consider their individual health circumstances and any potential risks or benefits associated with contraceptive use."
    },
    {
        "pregunta": "2. What is the preferred approach for patients at risk for osteoporosis in terms of contraceptive options?",
        "respuesta": "For patients at risk for osteoporosis, it is generally recommended to avoid contraceptive options that may negatively impact bone density. Depot medroxyprogesterone acetate (DMPA), an injectable form of contraception, is known to be associated with a reduction in bone mineral density. Therefore, it is often advised to use alternative contraceptive methods for those at risk of osteoporosis. Options such as oral contraceptive pills containing estrogen, the levonorgestrel-releasing intrauterine device (IUD), or barrier methods may be considered safer alternatives. However, it is essential for patients to consult with their healthcare provider to determine the most appropriate contraceptive method for their individual health needs and risk factors."
    },
    {
        "pregunta": "3. How should stress-dose glucocorticoids be administered during vaginal delivery according to the guideline?",
        "respuesta": "I don't know."
    },
    {
        "pregunta": "4. What is the recommended approach for continuing tumor necrosis factor inhibitor therapy during pregnancy?",
        "respuesta": "The recommended approach for continuing tumor necrosis factor (TNF) inhibitor therapy during pregnancy generally involves balancing the benefits of controlling maternal disease activity with the potential risks to the fetus. Many guidelines suggest that TNF inhibitors can be continued during pregnancy, particularly during the first and second trimesters, as they have not been shown to significantly increase the risk of congenital malformations. However, it is often recommended to discontinue TNF inhibitors during the third trimester, especially those that actively cross the placenta, to minimize potential immunosuppressive effects on the newborn. Each case should be individualized, and decisions should always be made in consultation with a healthcare provider specializing in maternal-fetal medicine or rheumatology."
    },
    {
        "pregunta": "5. How do biologic therapies vary in terms of placental transfer and fetal exposure during pregnancy?",
        "respuesta": "Biologic therapies vary in terms of placental transfer and fetal exposure during pregnancy primarily based on the structure and size of the molecules and the timing during gestation. Generally, the ability of biologics to cross the placenta depends largely on the type of antibody and the presence of the neonatal Fc receptor (FcRn). \n\n- **IgG antibodies**, particularly IgG1, are known to be actively transported across the placenta via FcRn, especially during the second and third trimesters. This means biologics that are IgG1 monoclonal antibodies can have significant placental transfer, leading to potential fetal exposure during these stages.\n\n- **IgG2, IgG3, and IgG4 antibodies** typically have a lower rate of placental transfer compared to IgG1.\n\n- **Large molecular weight biologics** like some fusion proteins or pegylated antibodies may have reduced placental transfer due to their size.\n\n- **Timing during pregnancy** is crucial as well. Placental transfer is minimal during the first trimester but increases significantly during the second and third trimesters.\n\nOverall, the degree of fetal exposure to biologic therapies depends on the specific characteristics of the biologic and the gestational age at which it is administered. It is important for healthcare providers to carefully consider these factors when prescribing biologic therapies to pregnant patients."
    },
    {
        "pregunta": "6. What is the panel's recommendation regarding the use of non-TNF inhibitor IgG-based molecules during the periconception period and pregnancy?",
        "respuesta": "I don't know."
    },
    {
        "pregunta": "7. How should treatment with rituximab be managed in women trying to conceive and during pregnancy?",
        "respuesta": "Rituximab is a monoclonal antibody that targets CD20-positive B cells and is used to treat various autoimmune conditions and certain types of cancer. Its use in women who are trying to conceive or who are pregnant requires careful consideration due to limited data on its safety during pregnancy.\n\n1. **Pre-Conception**: Women are generally advised to avoid becoming pregnant while receiving rituximab treatment. It is recommended to use effective contraception during treatment and for a period after the last doseâ€”typically about 12 months, although specific recommendations can vary based on guidelines and individual circumstances.\n\n2. **During Pregnancy**: The use of rituximab during pregnancy is generally not recommended unless the potential benefits to the mother outweigh the risks to the fetus. Rituximab can cross the placenta, especially in the second and third trimesters, and may affect fetal B-cell development, potentially leading to immunosuppression in the newborn.\n\n3. **Consultation with Healthcare Providers**: Women who are pregnant or planning to become pregnant should discuss their treatment options with their healthcare providers, including obstetricians and specialists managing their condition, to weigh the risks and benefits and to explore possible alternative treatments that may be safer during pregnancy.\n\nOverall, the management of rituximab treatment in women trying to conceive or who are pregnant should be personalized and closely monitored by healthcare professionals."
    },
    {
        "pregunta": "8. What is the guideline's stance on the use of small-molecule agents like tofacitinib, baricitinib, and apremilast during pregnancy?",
        "respuesta": "I don't know."
    },
    {
        "pregunta": "9. What are the recommendations for breastfeeding while on RMD medications such as HCQ, colchicine, and TNF inhibitors?",
        "respuesta": "The recommendations for breastfeeding while on medications for rheumatic and musculoskeletal diseases (RMDs) such as hydroxychloroquine (HCQ), colchicine, and TNF inhibitors generally support breastfeeding, but with considerations for each medication:\n\n1. **Hydroxychloroquine (HCQ):** It is considered safe to use during breastfeeding. HCQ is excreted into breast milk in small amounts, which are considered too low to cause harm to the infant. Most guidelines suggest that the benefits of breastfeeding outweigh the potential risks of HCQ exposure.\n\n2. **Colchicine:** Colchicine is also considered compatible with breastfeeding. Although it does pass into breast milk, the quantities are relatively low, and no adverse effects have been consistently reported in breastfed infants. However, monitoring for any potential side effects in the infant is advised.\n\n3. **TNF Inhibitors (such as infliximab, adalimumab, etanercept):** These biologics are generally considered safe for use during breastfeeding. They are large protein molecules and are present in breast milk in minimal amounts, which are unlikely to be absorbed in the infant's gastrointestinal tract. Therefore, the risk to the breastfed infant is considered low.\n\nIt is always crucial for breastfeeding mothers to discuss their specific medications with their healthcare provider to ensure that the benefits of treatment outweigh any potential risks to the infant."
    },
    {
        "pregunta": "10. How should breastfeeding be managed for women taking prednisone at different dose levels?",
        "respuesta": "Breastfeeding while taking prednisone generally depends on the dose. Here are some considerations:\n\n1. **Low Dose (up to 20 mg/day):** Prednisone is usually considered compatible with breastfeeding at low doses. The amount of the drug that passes into breast milk is minimal and unlikely to cause harm to the infant.\n\n2. **Moderate to High Dose:** For doses above 20 mg/day, caution is advised. It may be recommended to time breastfeeding to minimize infant exposure. For example, breastfeeding immediately before taking the dose can help reduce the infant's exposure, as the drug levels in breast milk will be lower by the next feeding.\n\n3. **Very High Dose:** At very high doses, it might be necessary to discuss with a healthcare provider about the risks versus benefits. In some cases, temporary weaning or formula supplementation might be considered if the medication is necessary for the mother's health.\n\nFor all dose levels, it is important to consult with a healthcare provider to get personalized advice based on the specific situation."
    }
]